CBF and cognitive evaluation of Alzheimer type patients before and after IMAO-B treatment

a pilot study

Alessandro Agnoli, Giovanni Fabbrini, Mario Fioravanti, Nicola Martucci

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

Ten patients diagnosed as affected by primary degenerative dementia of the Alzheimer type, with a mild to moderate cognitive and behavioral impairment, were studied in a double blind design when taking for 60 days 5 mg twice a day of L-deprenyl or placebp. Cognitive functions and cerebral blood flow were assessed at the beginning and at the end of treatment by a wide array of memory, attention, and language efficiency measures and by SPECT-99TcHMPAO procedure. Reduced CBF on the parietal lobes was demonstrated in the patients at baseline together with a reduction of memory and cognitive efficiency. At the end of the treatment patients who received L-deprenyl showed an improvement in cognitive efficiency and no changes in CBF, while patients treated with placebo showed a worsening of cognitive efficiency and further reduction of parietal lobe CBF.

Original languageEnglish
Pages (from-to)31-35
Number of pages5
JournalEuropean Neuropsychopharmacology
Volume2
Issue number1
DOIs
Publication statusPublished - 1992

Fingerprint

Efficiency
Selegiline
Parietal Lobe
Cerebrovascular Circulation
Therapeutics
Single-Photon Emission-Computed Tomography
Cognition
Alzheimer Disease
Language
Placebos
Cognitive Dysfunction

Keywords

  • Dementia
  • Monoamine oxidase inhibitors
  • single photon emission computed
  • Tomography

ASJC Scopus subject areas

  • Clinical Neurology
  • Psychiatry and Mental health
  • Biological Psychiatry
  • Neurology
  • Pharmacology
  • Psychology(all)

Cite this

CBF and cognitive evaluation of Alzheimer type patients before and after IMAO-B treatment : a pilot study. / Agnoli, Alessandro; Fabbrini, Giovanni; Fioravanti, Mario; Martucci, Nicola.

In: European Neuropsychopharmacology, Vol. 2, No. 1, 1992, p. 31-35.

Research output: Contribution to journalArticle

@article{afebf028f7f84a29b27a67130464ca2a,
title = "CBF and cognitive evaluation of Alzheimer type patients before and after IMAO-B treatment: a pilot study",
abstract = "Ten patients diagnosed as affected by primary degenerative dementia of the Alzheimer type, with a mild to moderate cognitive and behavioral impairment, were studied in a double blind design when taking for 60 days 5 mg twice a day of L-deprenyl or placebp. Cognitive functions and cerebral blood flow were assessed at the beginning and at the end of treatment by a wide array of memory, attention, and language efficiency measures and by SPECT-99TcHMPAO procedure. Reduced CBF on the parietal lobes was demonstrated in the patients at baseline together with a reduction of memory and cognitive efficiency. At the end of the treatment patients who received L-deprenyl showed an improvement in cognitive efficiency and no changes in CBF, while patients treated with placebo showed a worsening of cognitive efficiency and further reduction of parietal lobe CBF.",
keywords = "Dementia, Monoamine oxidase inhibitors, single photon emission computed, Tomography",
author = "Alessandro Agnoli and Giovanni Fabbrini and Mario Fioravanti and Nicola Martucci",
year = "1992",
doi = "10.1016/0924-977X(92)90033-5",
language = "English",
volume = "2",
pages = "31--35",
journal = "European Neuropsychopharmacology",
issn = "0924-977X",
publisher = "Elsevier Science B.V.",
number = "1",

}

TY - JOUR

T1 - CBF and cognitive evaluation of Alzheimer type patients before and after IMAO-B treatment

T2 - a pilot study

AU - Agnoli, Alessandro

AU - Fabbrini, Giovanni

AU - Fioravanti, Mario

AU - Martucci, Nicola

PY - 1992

Y1 - 1992

N2 - Ten patients diagnosed as affected by primary degenerative dementia of the Alzheimer type, with a mild to moderate cognitive and behavioral impairment, were studied in a double blind design when taking for 60 days 5 mg twice a day of L-deprenyl or placebp. Cognitive functions and cerebral blood flow were assessed at the beginning and at the end of treatment by a wide array of memory, attention, and language efficiency measures and by SPECT-99TcHMPAO procedure. Reduced CBF on the parietal lobes was demonstrated in the patients at baseline together with a reduction of memory and cognitive efficiency. At the end of the treatment patients who received L-deprenyl showed an improvement in cognitive efficiency and no changes in CBF, while patients treated with placebo showed a worsening of cognitive efficiency and further reduction of parietal lobe CBF.

AB - Ten patients diagnosed as affected by primary degenerative dementia of the Alzheimer type, with a mild to moderate cognitive and behavioral impairment, were studied in a double blind design when taking for 60 days 5 mg twice a day of L-deprenyl or placebp. Cognitive functions and cerebral blood flow were assessed at the beginning and at the end of treatment by a wide array of memory, attention, and language efficiency measures and by SPECT-99TcHMPAO procedure. Reduced CBF on the parietal lobes was demonstrated in the patients at baseline together with a reduction of memory and cognitive efficiency. At the end of the treatment patients who received L-deprenyl showed an improvement in cognitive efficiency and no changes in CBF, while patients treated with placebo showed a worsening of cognitive efficiency and further reduction of parietal lobe CBF.

KW - Dementia

KW - Monoamine oxidase inhibitors

KW - single photon emission computed

KW - Tomography

UR - http://www.scopus.com/inward/record.url?scp=0026827905&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026827905&partnerID=8YFLogxK

U2 - 10.1016/0924-977X(92)90033-5

DO - 10.1016/0924-977X(92)90033-5

M3 - Article

VL - 2

SP - 31

EP - 35

JO - European Neuropsychopharmacology

JF - European Neuropsychopharmacology

SN - 0924-977X

IS - 1

ER -